Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|August 31, 2026

The BioPharm Brief: New Approval, Trial Halt, and Updated Vaccine

Listen
0:00 / 0:00

Today’s BioPharm Brief looks at a new treatment for essential thrombocythemia, a halted cancer vaccine trial, and updated COVID-19 vaccine approvals ahead of the 2026-2027 season.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here are today’s top three stories in two minutes.

First, the FDA has approved PharmaEssentia’s Besremi, or ropeginterferon alfa-2b-njft, for adults with essential thrombocythemia, making it the first new FDA-approved treatment for the rare blood cancer in nearly 30 years. The approval covers adults regardless of genotype or disease status and is supported by the Phase 3 SURPASS-ET trial, where 43% of patients achieved a durable response compared with 6% receiving anagrelide. The therapy also reduced thromboembolic events over 12 months.

In oncology, BioNTech is stopping a phase 2 trial of its individualized mRNA cancer vaccine autogene cevumeran in resected colorectal cancer. The decision follows a recommendation from the trial’s independent Data Safety Monitoring Board, which identified a numerical imbalance in overall survival and concluded that continuing the study was unlikely to change the efficacy outcome. BioNTech said no new safety signals were identified. The company’s separate Phase 2 trial of autogene cevumeran in pancreatic cancer continues.

And ahead of the 2026-2027 vaccination season, Novavax’s updated Nuvaxovid has received approval in the US, EU, and Japan for the XFG variant. The protein-based, non-mRNA vaccine uses Novavax’s recombinant nanoparticle technology and Matrix-M adjuvant. The updated formulation is expected to roll out through Sanofi’s and Takeda’s distribution networks as the new vaccination season begins.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Besremi wins a new indication: FDA approved ropeginterferon alfa-2b-njft for adults with essential thrombocythemia, making it the first new FDA-approved treatment for the blood cancer in nearly 30 years.
  • BioNTech halts a phase 2 cancer vaccine trial: The company terminated its colorectal cancer study of autogene cevumeran following a data safety monitoring board review.
  • Nuvaxovid is updated for the 2026–2027 season: Novavax’s XFG-adapted vaccine has received approvals in the US, EU, and Japan ahead of the new COVID-19 vaccination season.

Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.